Milestone Pharmaceuticals (MIST) Research & Development (2018 - 2022)
Milestone Pharmaceuticals' (MIST) quarterly Research & Development came in at $9.8 million in Q3 2022, up 0.96% YoY from $9.7 million in Q3 2021, and down 7.8% on a QoQ basis from $10.7 million in Q2 2022.
Milestone Pharmaceuticals (MIST) Research & Development (2018 - 2022) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 5 years of Research & Development data on file, last reported at $9.8 million in Q3 2022.
- Quarterly Research & Development rose 0.96% year-over-year to $9.8 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $41.1 million (up 22.71% YoY) and the FY2021 annual result came in at $38.7 million, up 12.13% from the prior year.
- Research & Development fell to $9.8 million in Q3 2022, from $10.7 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $14.1 million in Q4 2019 to a low of $2.6 million in Q2 2018.
- A 5-year average of $8.5 million and a median of $9.0 million in 2020 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2019 — Research & Development soared 312.66% — and 2020, when it plunged 59.25%.
- Tracing MIST's Research & Development over 5 years: stood at $7.3 million in 2018, then soared by 93.9% to $14.1 million in 2019, then sank by 59.25% to $5.8 million in 2020, then soared by 89.32% to $10.9 million in 2021, then declined by 9.99% to $9.8 million in 2022.
- The last three Research & Development figures came in at $9.8 million (Q3 2022), $10.7 million (Q2 2022), and $10.9 million (Q4 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Milestone Pharmaceuticals | 42.70 Mn | -128.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 9.83 Mn |
| Jun 30, 2022 | 10.66 Mn |
| Dec 31, 2021 | 10.92 Mn |
| Sep 30, 2021 | 9.73 Mn |
| Jun 30, 2021 | 9.43 Mn |
| Mar 31, 2021 | 8.60 Mn |
| Dec 31, 2020 | 5.77 Mn |
| Sep 30, 2020 | 8.23 Mn |
| Jun 30, 2020 | 8.62 Mn |
| Mar 31, 2020 | 11.87 Mn |
| Dec 31, 2019 | 14.15 Mn |
| Sep 30, 2019 | 9.55 Mn |
| Jun 30, 2019 | 10.53 Mn |
| Mar 31, 2019 | 7.77 Mn |
| Dec 31, 2018 | 7.30 Mn |
| Sep 30, 2018 | 3.91 Mn |
| Jun 30, 2018 | 2.55 Mn |
| Mar 31, 2018 | 3.09 Mn |